Loading data
TCMDNasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 329.52 m USD | 292.98 m USD | 274.42 m USD | 246.79 m USD | 208.06 m USD |
| Cost of revenue | 79.38 m USD | 76.3 m USD | 79.29 m USD | 70.81 m USD | 59.84 m USD |
| Gross profit | 250.15 m USD | 216.69 m USD | 195.13 m USD | 175.98 m USD | 148.21 m USD |
| Research and development expense | 8.48 m USD | 8.83 m USD | 7.82 m USD | 7.09 m USD | 5.66 m USD |
| Operating profit | 29.28 m USD | 22.18 m USD | 18.04 m USD | -12.76 m USD | -1.76 m USD |
| Profit before tax | 31.34 m USD | 23.49 m USD | 15.77 m USD | -15.47 m USD | -2.29 m USD |
| Income tax expense | 12.25 m USD | 6.53 m USD | -12.75 m USD | 2.39 m USD | 9.52 m USD |
| Net income (reported basis) | 19.09 m USD | 16.96 m USD | 28.52 m USD | -17.87 m USD | -11.81 m USD |
| Net income attributable to common shareholders | — | — | — | -17.87 m USD | -11.81 m USD |
| Basic earnings per share | 0.83 USD/share | 0.71 USD/share | 1.24 USD/share | -0.89 USD/share | -0.6 USD/share |
| Diluted earnings per share | 0.82 USD/share | 0.7 USD/share | 1.23 USD/share | -0.89 USD/share | -0.6 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.